Sun Pharmaceutical Industries shares fell more than 2 percent in early trade on September 1, paring three-session gains after the drugmaker agreed to lower US drug prices in return for tariff concessions. Sun Pharma agreed to extend Most Favored Nation (MFN) pricing to US state Medicaid programmes and future innovative medicine launches as part of an agreement with the US government.